2-bromo-5-(4-fluorophenyl)pyrazine | 153295-35-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-5-(4-fluorophenyl)pyrazine
• CAS: 153295-35-3
• 化学式: C₁₀H₆BrFN₂
• 分子量: 253.073
• InChiKey: PLPAAJCOMZOXAI-UHFFFAOYSA-N

物化性质

• 沸点：
  315.1±37.0 °C(Predicted)
• 密度：
  1.566±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 储存条件：
  | 室温 |

反应信息

• 作为反应物：
  描述：

  4-乙酰吡啶 、 2-bromo-5-(4-fluorophenyl)pyrazine 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.17h， 以24%的产率得到1-(5-(4-fluorophenyl)pyrazin-2-yl)-1-(pyridin-4-yl)ethanol
  参考文献：
  名称：

  [EN] PYRIDINE DERIVATIVES
  [FR] DÉRIVÉS PYRIDINES

  摘要：

  本申请提供了新型的吡啶化合物及其药用可接受的盐或前药。同时，还提供了制备这些化合物的方法。这些化合物通过向患者施用一种或多种化合物的治疗有效量，用于抑制CYP 17活性。通过这样做，这些化合物有效地治疗与CPY17活性相关的病症。可以使用这些化合物治疗多种病症，包括以异常细胞增殖为特征的疾病。在一个实施例中，所述疾病为癌症，如前列腺癌。

  公开号：

  WO2013049559A1
• 作为产物：
  描述：

  5-(4-fluorophenyl)pyrazin-2-amine 在 三溴甲烷 、 亚硝酸异戊酯 作用下， 生成 2-bromo-5-(4-fluorophenyl)pyrazine
  参考文献：
  名称：

  EP1657242

  摘要：

  公开号：

文献信息

• PYRIDINE DERIVATIVES
  申请人：Asana BioSciences, LLC

  公开号：US20170073339A1

  公开（公告）日：2017-03-16

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。还提供了制备这些化合物的方法。通过向患者投入一种或多种化合物的治疗有效剂量，这些化合物可用于抑制CYP17活性。通过这样做，这些化合物可有效治疗与CYP17活性有关的疾病。这些化合物可用于治疗多种疾病，包括以异常细胞增殖为特征的疾病。在一种实施方式中，该疾病是癌症，如前列腺癌。
• Imidazopyridine Derivatives
  申请人：Kishino Hiroyuki

  公开号：US20080200494A1

  公开（公告）日：2008-08-21

  The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R 1 and R 2 may be the same or different and stand for C 1-6 alkyl or the like, R 3 and R 4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.

  该发明提供了由通式[I]表示的咪唑吡啶衍生物 [其中R1和R2可能相同或不同，且代表C1-6烷基或类似物，R3和R4代表氢原子，甲基基团或类似物，W代表单环或双环的3-8元芳香或脂肪杂环或类似物，Ar代表可选择取代的芳香杂环或类似物]。这些化合物作为黑色素浓集激素受体拮抗剂，可用于治疗中枢神经系统疾病、心血管系统疾病和代谢性疾病的药物。
• Pyridine Derivatives
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20130085148A1

  公开（公告）日：2013-04-04

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。同时还提供了制备这些化合物的方法。这些化合物可以通过向患者投予治疗有效量的一个或多个化合物来抑制CYP17活性。通过这样做，这些化合物对于治疗与CPY17活性相关的疾病是有效的。这些化合物可以用于治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症，如前列腺癌。
• Pyridine derivatives
  申请人：Endo Pharmaceuticals, Inc.

  公开号：US08809372B2

  公开（公告）日：2014-08-19

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。还提供了制备这些化合物的方法。这些化合物可通过向患者投予治疗有效量的一个或多个化合物来抑制CYP17活性。通过这样做，这些化合物可有效治疗与CYP17活性有关的疾病。这些化合物可用于治疗多种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症，如前列腺癌。
• IMIDAZOPYRIDINE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1657242A1

  公开（公告）日：2006-05-17

  The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R1 and R2 may be the same or different and stand for C1-6 alkyl or the like, R3 and R4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.

  本发明提供由通式[I]代表的咪唑吡啶衍生物[其中 R1 和 R2 可以相同或不同，代表 C1-6 烷基或类似物，R3 和 R4 代表氢原子、甲基或类似物，W 代表单环或双环 3 至 8 元芳香族或脂肪族杂环或类似物，Ar 代表任选取代的芳香族杂环或类似物]。这些化合物具有黑色素浓缩激素受体拮抗剂的作用，可作为治疗中枢神经系统疾病、心血管系统疾病和代谢紊乱的药物。